**6. Conclusions**

Cancer is a multifactorial disease with varieties of treatment options available, depending upon the location, drug delivery and stage of cancer. Optimization of immune response to curb the growth, proliferation and containment of cancer has been chosen in TIL, TCR T cell and CAR T cell therapy. Growing technologies in cell biology are improving the future promises for further breakthroughs in the T cell ACT field. Various future domains, which are being explored for further improvements are being discussed below [75]:


In short, advantages versus toxicities of the anti-cancer therapy have to be considered before deciding the treatment modalities. Ultimately, successful implementation of ACT as the clinical program and cost minimization will determine its success across the globe.
